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Single-Chain Fv-Based Anti-HIV Proteins: Potential and Limitations
Anthony P. West, Jr.,a Rachel P. Galimidi,a Priyanthi N. P. Gnanapragasam,a and Pamela J. Bjorkmana,b
Division of Biologya and Howard Hughes Medical Institute,b California Institute of Technology, Pasadena, California, USA
The existence of very potent, broadly neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) offers the
potential for prophylaxis against HIV-1 infection by passive immunization or gene therapy. Both routes permit the delivery of
modified forms of IgGs. Smaller reagents are favored when considering ease of tissue penetration and the limited capacities of
gene therapy vectors. Immunoadhesin (single-chain fragment variable [scFv]-Fc) forms of IgGs are one class of relatively small
reagent that has been explored for delivery by adeno-associated virus. Here we investigated the neutralization potencies of im-
munoadhesins compared to those of their parent IgGs. For the antibodies VRC01, PG9, and PG16, the immunoadhesins showed
modestly reduced potencies, likely reflecting reduced affinities compared to those of the parent IgG, and the VRC01 immunoad-
hesin formed dimers andmultimers with reduced neutralization potencies. Although scFv forms of neutralizing antibodies may
exhibit affinity reductions, they provide a means of building reagents with multiple activities. Attachment of the VRC01 scFv to
PG16 IgG yielded a bispecific reagent whose neutralization activity combined activities from both parent antibodies. Although
the neutralization activity due to each component was partially reduced, the combined reagent is attractive since fewer strains
escaped neutralization.
Developing an effective human immunodeficiency virus type 1(HIV-1) vaccine has been a great challenge for more than 25
years. Results from the RV144 vaccine trial in Thailand suggested
that a partial degree of protection from infection was achieved
(32), but whether and how a more effective vaccine can be devel-
oped remain open questions (39, 40). Difficulties in making an
effective vaccine result in part from the humoral immune re-
sponse against HIV-1, in which the antibodies produced are gen-
erally strain specific and can be quickly evaded by the rapidly
mutating virus (43).Highly potent cross-strain anti-HIV antibod-
ies have been isolated (5, 35, 41, 42, 45), but the unresolved prob-
lem is how to elicit these rare antibodies.
Although neutralizing antibodies have shown limited efficacy
for controlling an established HIV-1 infection (26, 31, 38), the
observation that most new infections appear to be initiated by
only one or a few viral particles (17, 33, 34) highlights the potential
for antibodies to provide sterilizing immunity. Passive immuni-
zation studies with broadly neutralizing antibodies have demon-
strated their ability to protect animals fromanHIV/simian immu-
nodeficiency virus (SIV) chimera challenge (2, 11–13, 23, 24, 29,
30, 36). Hence, an alternative approach to prophylaxis is to deliver
the genes for potent anti-HIV proteins to provide long-lasting
protection. A successful demonstration of this approach in rhesus
macaques using adeno-associated virus (AAV) as the gene deliv-
ery vehicle has been achieved (15). AAV is an attractive vector due
to its long-term gene expression and low toxicity (10). However,
the use of AAV vectors imposes a size restriction on the gene
delivered: expression fromAAV vectors with genomes larger than
4,900 bases is greatly attenuated (7). This can make it difficult to
use AAV for delivery of large proteins, such as IgG antibodies,
which include a heavy chain (HC) with four domains (the Fab
heavy (VH) and constant heavy 1 (CH1) domains and the Fc CH2
and CH3 domains) and a light chain (LC) with two domains (the
Fab variable light (VL) and constant light (CL) domains) (Fig. 1).
Self-complementary AAVvectors are onemeans of achieving high
expression levels (25); however, size restrictions for these vectors
prevent simultaneous incorporation of conventional antibody
heavy and light chain genes.
To achieve high transduction levels, a smaller immunoglob-
ulin architecture was used in the AAV-mediated gene therapy
experiments in rhesus macaques (15): single-chain fragment
variable (scFv) units attached to an Fc domain (an scFv immu-
noadhesin comprising IgG VH, VL, CH2, and CH3 domains, here
referred to as an immunoadhesin or IA) (Fig. 1). A wide variety of
Fc fusions have been developed over the last 20 years to take ad-
vantage of this architecture’s key benefits: avidity provided by ho-
modimeric Fc, serumpersistence provided by the Fc region due to
FcRn-mediated protection from catabolism, and a size large
enough to avoid filtration by the kidneys (14). An scFv unit, in
which VH is fused to VL with a short linking region usually com-
posed of glycines and serines, generally retains the antigen binding
functionality of its parent Fab, although scFv is only about 1/2 the
size of an intact Fab. Although scFv-based reagents have been
under development formany years, their overall potential as drugs
remains uncertain (28).
Several broadly neutralizing and highly potent antibodies
against HIV-1 have recently been isolated from infected individ-
uals. Two such antibodies, PG9 and PG16, target a quaternary
epitope involving the V1-V2 and V3 variable loops of gp120 (42).
Another class of antibodies, typified by antibody VRC01, targets
the CD4-binding site of gp120 (44). The efficacy of gene therapy
reagents derived from these antibodies depends on a number of
factors, including their potency, strain coverage, in vivo stability,
effector function, and serum concentrations that can be achieved.
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To help inform decisions relating to the architecture of potential
reagents, we systematically compared the potencies of IAs with
their IgG and Fab counterparts. We also explored the potential to
combine VCR01 and PG9/PG16 activities to produce a single re-
agent with two gp120 specificities.
MATERIALS AND METHODS
Materials. Sequences for all constructs are in Fig. S1 in the supplemental
material. VRC01 IgG was expressed using plasmids VRC8551 and
VRC8552, provided by Gary Nabel (Vaccine Research Center, NIH).
VRC01 Fab was expressed using a truncated VRC8552 heavy chain gene
sequence encoding a 7-His tag and stop codon after the CH1 domain.
VRC01 IgG-2A was expressed using plasmid VRC9715, which contains a
picornavirus 2A peptide sequence (37) between the heavy and light chain
genes. VRC01 IA was expressed using plasmid VRC9713 (provided by
Gary Nabel), which encodes an IA protein in which a VRC01 scFv [VH
domain connected via a (Gly3Ser)4 linker to theVL domain] is fused to the
Fc region from human IgG1. A VRC01 scFv gene was constructed by
truncating the VRC01 IA gene by inserting a 6-His tag and stop codon
after the VL domain.
Genes encoding the variable regions (VH and VL) or the intact light
chain (VL-CL) of PG9 and PG16 antibodies (Abs) were synthesized (Blue-
Heron Biotechnologies or Integrated DNA Technologies) based on se-
quences provided by Dennis Burton (The Scripps Research Institute).
Intact IgG genes were constructed by subcloning the relevant variable
sequences onto a human IgG1 sequence. The designs of the PG9 andPG16
IAs were patterned after the rhesus IAs described previously (15); thus,
PG9 IA was constructed as VH-(Gly4-Ser)3-VL-Fc, and PG16 IAs were
constructed as VL-(Gly4-Ser)3-VH-Fc and VH-(Gly4-Ser)3-VL-Fc; for
these IAs, the Fc sequence was that of human IgG2. PG9 and PG16 Fabs
were expressed using truncated heavy chains with additional 7-His tags.
The PG9 and PG16 constructs were subcloned into the mammalian ex-
pression vector pTT5 (NRC Biotechnology Research Institute). The scFv
genes for PG9 and PG16 were constructed by inserting a 6-His tag and
stop codon after the second variable domain.
VRC01scFv-PG16, VRC01scFv-ZAG3-Fc, and VRC01scFv-E51 were
constructed by combining the scFv gene from VRC01 IA with IgG heavy
chain or Fc fusion constructs by PCR and enzymatic ligation techniques.
All gene constructs were verified by complete sequencing.
Protein expression and purification. Proteins were expressed tran-
siently in suspension HEK 293-6E cells (NRC Biotechnology Research
Institute) using 25-kDa linear polyethylenimine (PEI) (Polysciences) for
transfection as described previously (8). When expressing heterodimeric
constructs, the heavy chain (HC) and light chain (LC) plasmids were
mixed at a 1:1 ratio by mass. Cell culture supernatants were collected 6
days posttransfection. For Fc-containing constructs, supernatants were
passed over protein A resin (Thermo Fisher Scientific), eluted using pH
3.0 citrate buffer, and then immediately neutralized. 7-His-tagged Fabs
and scFvs were purified using nickel-nitrilotriacetic acid (Ni-NTA) chro-
matography and eluted using 300 mM imidazole. All reagents tested in
neutralization assays were purified by size exclusion chromatography us-
ing a Superdex 200 10/300 GL column.
In vitro neutralization assays. A previously described pseudovirus
neutralization assay was used to evaluate the neutralization potencies of
the reagents (21, 27). Neutralization assays were performed either by the
Collaboration for AIDS Vaccine Discovery (CAVD) core neutralization
facility (Table 1; see also Tables S1 and S2 in the supplementalmaterial) or
by our laboratory (Table 2) using the same protocol (21, 27). Briefly,
pseudoviruseswere generated by cotransfection ofHEK293T cells with an
Env expression plasmid and a replication-defective backbone plasmid.
Neutralization was determined by measuring the reduction in luciferase
reporter gene expression in the presence of a potential inhibitor following
a single round of pseudovirus infection in TZM-bl cells. Nonlinear regres-
sion analysis was used to calculate the concentrations at which half-
maximal inhibition was observed (IC50s).
Biosensor affinity measurements. A Biacore 2000 biosensor system
(GE Healthcare) was used to evaluate the interactions of VRC01 reagents
with gp120. Approximately 750 response units (RUs) of protein A was
covalently immobilized on all flow cells of a CM5 biosensor chip using
standard primary amine coupling chemistry (Biacore manual). VRC01
IA, VRC01scFv-ZAG3-Fc, and VRC01 IgG were then bound to three of
the individual flow cells (1,400 RUs each), with the fourth flow cell
serving as a blank. A concentration series of gp120 from strainQ259.d2.17
(expressed in baculovirus-infected insect cells as described previously [6])
was injected at room temperature in 10 mMHEPES with 150 mM NaCl,
3 mM EDTA and 0.005% surfactant P20 at pH 7.4. Equilibrium dissoci-
ation constants (KDs) were determined from kinetic constants derived
from sensorgram data using simultaneous fitting to the association and
dissociation phases of the interaction.
RESULTS
In order to compare the neutralization potencies of various anti-
body forms, we produced IgG, IA, and Fab forms of the anti-HIV
antibodies PG9, PG16, and VRC01 (42, 44) (Fig. 1). We also pro-
duced the PG9 scFv but were unable to express either the VRC01
or PG16 scFvs in isolation in sufficient quantities for testing. Pro-
teins were expressed by transient transfection ofmammalian cells,
and purification was by protein A or Ni-NTA chromatography
followed by size exclusion chromatography. The size exclusion
chromatography profiles of the PG9 and PG16 IAs revealed large
peaks corresponding to the expected products (Fig. 2), i.e., a single
Fc unit with two scFvs, whichwewill subsequently refer to as an IA
monomer. During size exclusion chromatography of the VRC01
IA, however, both aggregated and apparently dimeric forms were
observed in addition to the expected product (Fig. 2). These larger
forms were a significant fraction of the material eluted from pro-
tein A chromatography, in contrast to the PG9 and PG16 IA pu-
rifications, in which only trace amounts of larger oligomers were
observed.
The proteins were evaluated in an Env-pseudotyped HIV-1
neutralization assay against a panel of 30 strains (Table 1; see also
Table S1 in the supplemental material). As observed for other
FIG 1 Schematic depiction of antibody reagent architectures. VH, variable
domain of the IgG heavy chain (HC); VL, variable domain of the IgG light
chain (LC); CH1, constant region 1 of the HC; CL, constant region of the LC;
Fc, CH2 and CH3 domains of dimerized HCs; scFv, single-chain fragment
variable (VH andVL domains of an IgG). The scFv shown is VH followed byVL;
scFvs can also be constructed as VL followed by VH.
West et al.
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anti-HIV antibodies, the Fab forms were on average 5- to 10-fold
less potent on a molar basis than the intact IgG (18). The 2A form
of VRC01 IgG (translated from a single mRNA containing a pi-
cornavirus 2A peptide sequence [37] between the heavy and light
chain genes) had potency equal to that of VRC01 IgG. However,
the IA forms of VRC01, PG9, and PG16 were less potent than the
corresponding IgGs; the potencies were reduced overall by 5.9-
fold (VRC01), 3.3-fold (PG9), and 15.5-fold (PG16 IA, con-
structed as VL followed by VH). Two-tailed paired t tests demon-
strated that these differences were significant (P values of 0.00045,
0.047, and 0.032, respectively). A PG16 IA constructed with VH
followed by VL was also expressed and tested on a more limited
number of strains; this reagent was also less potent than PG16 IgG
(see Table S2 in the supplemental material). Although the dimeric
fraction of the VRC01 IA was active in neutralization, it was 2.3-
fold less potent on a mass basis (P value of 0.00012) than mono-
meric VRC01 IA (Table 1).
Potential reasons for the IAs to be less potent than their parent
IgGs include the following: (i) a shorter span between the two
antigen combining sites, (ii) reduced stability of IAs versus IgGs in
the assay media, and/or (iii) reduced affinity of the scFv antigen
binding sites compared to that of Fab binding sites. To evaluate
whether the shorter arm span of the IAs diminished their activity,
we expressed an scFv-containing reagent with a combining site
separation more similar to that of IgG by inserting an immuno-
globulin constant region-like domain, the3 domain fromZn-2
glycoprotein (ZAG), between the scFv and Fc components to cre-
ate VRC01scFv-ZAG3-Fc (Fig. 1). The maximal separation be-
tween the VH-VL combining sites should be similar in VRC01scFv-
ZAG3-Fc and VRC01 IgG. To permit even greater separation,
the VRC01 scFv was also attached to the N terminus of the heavy
chain of an unrelated IgG to create VRC01scFv-E51. The CD4-
induced (CD4i) antibody E51 was chosen for this construct be-
cause E51 IgG expresses well and is weakly neutralizing or non-
neutralizing in the absence of CD4 (22), as observed for other
CD4i antibodies (19). Neutralization assays using these reagents
(Table 1) demonstrated an average IC50 similar to that with
VRC01 IA, indicating that the arm span of VRC01scFv-based re-
agents had little impact on their neutralization potencies.
We next tested whether differences in reagent stability (i.e.,
survival) under our neutralization assay conditions contributed to
the differences we observed between IAs and IgGs by conducting
assays with a 12- or 24-h preincubation in assay medium prior to
adding pseudovirus. No trend toward diminished neutralization
potency over time was observed (Table 2), demonstrating that
differential stability in the assay medium did not account for dif-
ferences in potency.
A weaker antigen-binding affinity of the scFv in an IA versus
the Fab in an IgG was suggested by the less potent neutralization
observed for PG9 scFv than for PG9 Fab (Table 1). The possibility
of reduced antigen-binding affinity was directly tested by compar-
ing the binding of gp120 to VRC01 IgG versus scFv-containing
TABLE 2 Effect of preincubation of VRC01 reagents on neutralization
potencya
Pseudovirus Reagent
IC50 (nM) of reagent at
preincubation time
0 h 12 h 24 h
JR-FL VRC01 IgG 0.37 0.40 0.31
VRC01 IA 5.2 4.6 1.7
Du156 VRC01 IgG 0.67 0.60 0.47
VRC01 IA 3.1 2.6 2.0
a The neutralization assay was modified by incubating the reagent in assay medium for
the indicated times prior to addition of pseudovirus.
FIG 2 Size exclusion chromatography profiles of PG16, PG9, and VRC01 IAs. Protein A-purified IAs were injected over a Superdex 200 10/300 GL column. IgGs
normally elute at13ml (as indicated at the top of the figure), compared to the slightly smaller IAmonomers, which elute at14.5 ml. (Data are shown for the
VL-VH version of the PG16 IA; similar results were obtained for the VH-VL version.) Although the PG9 and PG16 IAs were predominantly monomeric, the
VRC01 IA profile showedmultimeric (presumably dimeric) and aggregate peaks in addition to themonomer. The tendency of scFvmolecules to dimerize by 3-D
domain swapping (shown schematically at the top in the box) may lead to the formation of dimeric and oligomeric forms of IAs (potential structures shown in
the box).
West et al.
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forms of VRC01. Purified gp120 from strain Q259.d2.17 was in-
jected over protein A-immobilized VRC01 IgG, VRC01 IA, or
VRC01scFv-ZAG3-Fc in a surface plasmon resonance (SPR)-
based binding assay (see Fig. S2 in the supplementalmaterial). The
equilibrium dissociation constant (KD) derived for VRC01 IgG
was 160 nM, compared with affinities of 590 nM and 570 nM for
VRC01 IA and VRC01scFv-ZAG3-Fc, respectively. The approxi-
mately 4-fold-weaker affinity of the scFv-containing reagents was
comparable to the 6-fold-weaker neutralization IC50 of VRC01 IA
compared to that of VRC01 IgG.
To explore the potential for combined reagents to provide
greater neutralization breadth, we expressed a modified form of
PG16 in which a VRC01 scFv was attached to the N terminus of
the PG16 light chain with a (Gly3-Ser)6 linker. The neutralization
properties of VRC01scFv-PG16 are shown in Table 1. Inspection of
the measured IC50s for strains that were resistant to either VRC01
or PG16 confirmed that both components in the combined re-
agent were active.
We assessed the potencies of each of the components in the
bispecific VRC01scFv-PG16 reagent by a modeling procedure us-
ing the IC50s for VRC01 IgG and PG16 IgG as follows. Assume the
IC50s of the parent IgGsVRC01 andPG16 are v and p, respectively,
for a given HIV-1 strain. Consider an idealized combined reagent
in which both components functioned independently with no
synergy or interference. In a very simplified picture of virus neu-
tralization, reagent binding is equivalent to neutralization, and the
IC50 can be approximated by a single binding event with the same
equilibrium dissociation constant. Solving the equilibrium equa-
tions for 50% binding/neutralization, we found the modeled IC50
was v2 6vpp2 v p⁄2. In the actual bispecific reagent, we
anticipated the individual components would have reduced activ-
ity, i.e., vreduced veff v, where veff is1, and preduced peff p,
where peff is 1. Assuming that veff and peff are constant across
different strains, we solved for best-fit values of these parameters
that minimized strains(log IC50 observed  log IC50 modeled)2. A fit
assuming only one active antibody did not fit the data as well as a
fit assuming that both components were active (see Fig. S3 in the
supplemental material).
Using our neutralization data for VRC01scFv-PG16 (Table 1),
we derived values of 3.16 and 3.22 for veff and peff; thus, the VRC01
scFv component possessed about 1/3 of the potency of VRC01
IgG, and the PG16 IgG portion possessed about 1/3 of the potency
of unmodified PG16 IgG. For any given strain, the combined re-
agent was nearly always weaker than the stronger parent IgG.
However, the combined reagent was superior on a mass basis to
theweaker parent for 27 out of 30 strains (Fig. 3, bottompanel). In
addition, the combined reagent neutralized more strains than ei-
ther parent; e.g., using an IC50 of 5.0 g/ml as the cutoff for
neutralization, VRC01scFv-PG16 neutralized 90%of the strains we
tested, while VRC01 IgG neutralized 83% and PG16 IgG neutral-
ized 70%(Table 1 andFig. 3, top panel).However, this depends on
the neutralization threshold chosen. For IC50s of1.0 g/ml, the
combined reagent neutralized 67% of strains, while VRC01 and
PG16 neutralized 77% and 60%, respectively.
DISCUSSION
Provision of prophylactic or therapeutic antibodies by direct in-
jection or gene therapy permits consideration of a wide range of
potential reagents, building on initial discoveries of anti-HIV
IgGs. Variations fall into threemajor categories: (i) those affecting
the antigen binding site, (ii) choice of the overall architecture (e.g.,
IA versus IgG), and (iii) modulations of effector function. A thor-
ough evaluation of the efficacies of the full range of potential re-
agents is a large task. A variety of selection strategies is available to
screen variants in category i, i.e., natural antibody repertoires and
antigen binding site libraries. However, full exploration of the
alternatives in categories ii and iii is limited by the need to produce
purified, testable quantities of reagents and the screening limita-
tions of evaluating effector function in complex cell- or animal-
based assays. The present studies are intended to provide insight
into the potential effects of architecture on reagent potency.
The size of a delivered reagent must be considered for gene
therapy efforts involving AAV. In general, constructs approaching
the size limit for packaging AAV suffer reduced expression levels
(7). Although the minimum serum or genital tract anti-HIV IgG
concentration necessary for protection is not known, a rough es-
timate of 100 times the reagent’s IC50 has been suggested (30). For
broad strain coveragewith reagents such asVRC01, PG9, or PG16,
this implies desired concentrations in the tens to hundreds of
g/ml. Early efforts using an AAV vector with separate promoters
for heavy and light chains directing expression of anti-HIV IgG
b12 yielded serum concentrations of only 5 g/ml (20). Alter-
native AAV/IgG constructs have permitted high-level IgG ex-
pression in other cases. For example, use of a single promoter
with a 2A self-processing peptide inserted between the anti-
body heavy and light chains permitted1-mg/ml IgG levels to
be achieved with AAV-transduced liver expression (9). Never-
theless, the smaller size of IA constructs versus conventional
IgG is attractive for gene therapy approaches in which vector
capacity is severely limited—in particular, for self-
complementary AAV vectors, which are more efficient at trans-
duction than AAV vectors with a single-stranded genome (25).
Tomore fully understand the potential trade-offs in vector and
construct design, we compared the neutralization activities of IA
versus IgG versions of three broadly neutralizing antibodies: PG9,
PG16, and VRC01 (42, 44). We found that the PG9, PG16, and
VRC01 IAs were severalfold less potent than their IgG forms. A
reduced affinity of the scFv antigen-binding site is a likely contrib-
uting factor to this difference. Although some scFvs have affinities
equivalent to those of the related Fabs, it was noted in early studies
that scFvs can exhibit up to 10-fold weaker binding (4). The
weaker binding and neutralization by the VRC01 scFv-containing
reagents is likely due to suboptimal geometry of the antigen bind-
ing site and/or steric interference by the Gly-Ser linker joining the
VRC01 VH and VL domains. Steric interference from the scFv
linker is consistent with the VRC01 Fab-gp120 crystal structure
(45), in which the N terminus of the Fab light chain is8 Å from
the gp120 backbone. This relatively close distance suggests that the
Gly-Ser linker extending from the VL domain N terminus could
sterically interfere with antigen binding. It is possible that the
scFvs in the reagents we tested were suboptimal; different designs
might yield scFvs with affinities matching those of the corre-
sponding Fabs. Thus, to achieve maximal efficacy, it will be nec-
essary to explore different architectures (VH-VL versus VL-VH)
and different linker lengths for each scFv used in IAs.
A potential complication of scFv reagents is their tendency to
dimerize or multimerize by three-dimensional (3-D) domain
swapping (3). The extent of dimerization of scFvs is variable, de-
pending on linker length, antibody sequence, concentration, buf-
fer conditions, and the presence or absence of antigen (1). The
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potential for IAs to form dimers or other oligomers as observed
for VRC01 IA is a special concern for reagents that will be deliv-
ered by gene therapy, where it is not possible to remove higher-
order products once they are secreted from transduced cells. Mul-
timeric forms of IAs may be less potent and potentially more
immunogenic than the monomeric molecule; this may add to the
immunogenicity of the artificial linker of IAs. AAV-mediated ex-
pression of IAs in rhesus macaques led to various levels of IA-
specific antibody response, which appeared to be correlated with
reduced efficacy against viral challenge (15). The best means of
addressing this possible complication is careful biophysical char-
acterization of proposed gene therapy protein products.
In the recent rhesus macaque SIV challenge experiment, deliv-
ery of IAs was found to be superior to either scFv or whole IgG
with respect to the serum concentrations that could be achieved
(15). Although the IAs used in the challenge experiments exhib-
ited neutralization IC50s well below 1.0 g/ml, the Fabs from
which they were derived had IC50s that were 3-fold more potent
on a mass basis (16). (The IC50s of the corresponding IgGs have
not been reported). On a molar basis, the IAs were thus about
FIG 3 Histograms displaying IC50s (g/ml) of VRC01 IgG (red), PG16 IgG (blue), and VRC01scFv-PG16 (purple) (top; linear scale) or VRC01 IgG (red), PG16
IgG (blue), VRC01scFv-PG16 (purple), and the modeled IC50s of VRC01scFv-PG16 (light purple) (bottom; logarithmic scale).
West et al.
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1.5-fold less potent than the Fab forms. This ratio is very similar to
the average 1.2-fold- and 1.5-fold-weakermolar neutralizationwe
observed for the VRC01 and PG16 IAs versus the corresponding
Fabs (Table 1). In the rhesus challenge study, the IA potencies
(IC50s of 0.01 to 0.02 g/ml against the SIVmac316 challenge
strain) were sufficient to provide protection. However, since anti-
HIV IgGs are generally 6- to 30-fold more potent than their cor-
responding Fabs on a molar basis (18), the IAs evaluated here
represent a significant trade-off necessitated by the lower serum
IgG concentrations achievable (15) with currently available AAV
technology.
While VRC01, PG9, and PG16 have very broad activities, each
of these antibodies fails to neutralize 9 to 27% of HIV-1 strains
(using a cutoff IC50 of 50 g/ml; at 1 g/ml, 28 to 49% of strains
are not neutralized) (42, 44). For passive immunization or gene
therapy applications, addressing the incomplete strain coverage
requires delivering either multiple antibodies or a single reagent
combining two or more activities. Here we investigated the feasi-
bility of one such bispecific reagent, in which a VRC01 scFv was
attached to PG16 IgG (VRC01scFv-PG16). In vitro neutralization
assays against a panel of HIV-1 strains demonstrated both VRC01
and PG16 activities. Although both potencies were reduced com-
pared to those of the parental IgGs, VRC01scFv-PG16 showed
greater breadth, suggesting the potential for a bispecific reagent to
provide complete or near-complete protection against HIV-1.
Further development of such a reagent is possible, for example,
given that the VRC01 scFv component of VRC01scFv-PG16 had a
reduced activity similar to that observed for the VRC01 IA, im-
provement of the scFv portion could be attempted. The weaker
activity of the PG16 component may result from steric factors
from the scFv attached to the N terminus of the PG16 light chain.
Switching the VRC01 scFv to the N terminus of the PG16 heavy
chain did not improve PG16 activity (see Table S3 in the supple-
mental material). Changing the size or structure of the linker or
switching to the C terminus of the heavy chainmay permit greater
PG16 activity. Although the reduced potencies of the individual
components of a bispecific reagent might increase the risk that
resistance to these neutralizing activities could develop, this con-
cern is arguably secondary to providing breadth of coverage in the
context of infection prophylaxis (versus treatment) since the goal
of infection prophylaxis is to neutralize a small viral inoculum
rather than to control an established infection.
The design of gene therapy reagents for HIV-1 prophylaxis
potentially involves a variety of trade-offs, including breadth of
reagent, potency, expression level, and minimization of potential
for immunogenicity and other side effects. The newly discovered
anti-HIV antibodies (42, 44) demonstrate that breadth and great
potency can be achieved simultaneously. Our results suggest that
careful optimization of reagent architecture and full biophysical
characterization of the oligomeric states of potential protein re-
agents are important for fully exploiting the potential offered by
genetic approaches to providing HIV-1 immunity. Direct conver-
sion of IgGs to IAs will often entail a loss of potency due to weaker
binding of the scFv compared to the Fab binding site and/or do-
main swapping to create scFv multimers, which can perhaps be
avoided by screening many scFv designs. Whether this loss of po-
tency is acceptable depends on relative in vivo serum levels of
AAV-expressed IAs and IgGs. For prophylaxis against a wide va-
riety of circulating HIV-1 strains, a delivered reagent will face
strains where its activity is far from maximal. In this situation,
optimization of the reagent will be critical to provide robust pro-
tection.
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